Table 2.
Onset, offset and overall glucose‐lowering effect for faster aspart (n = 44) and insulin aspart (n = 45) after a bolus dose of 0.15 U/kg administered by CSII
| Faster aspart 1 | Insulin aspart 1 | Treatment ratio 2 (95% CI) | Treatment difference 3 (95% CI) | P | |
|---|---|---|---|---|---|
| Onset of glucose‐lowering effect, min | |||||
| tEarly 50% GIRmax | 41.1 | 52.3 | 0.79 (0.72; 0.86) | −11.1 (−15.4; −6.9) | <.001 |
| tGIRmax | 111.9 | 130.6 | 0.86 (0.75; 0.97) | −18.7 (−34.4; −2.9) | .021 |
| Offset of glucose‐lowering effect, min | |||||
| tLate 50% GIRmax | 214.7 | 238.7 | 0.90 (0.84; 0.96) | −24.0 (−38.9; −9.1) | .002 |
| Overall glucose‐lowering effect | |||||
| AUCGIR,0‐t, mg/kg | 1341.5 | 1295.7 | 1.04 (0.95; 1.13) | NA | .427 |
| GIRmax, mg/kg/min | 7.1 | 6.8 | 1.04 (0.94; 1.14) | NA | .439 |
NA, not applicable; t, time of first non‐positive baseline infusion corrected GIR in the terminal part of the smoothed GIR profile (however, no longer than 12 hours).
1
Data are least squares means.
2
Faster aspart/insulin aspart (for onset and offset of glucose‐lowering effect endpoints, the treatment ratio was calculated using Fieller's method).
3
Faster aspart – insulin aspart.